Status:

RECRUITING

Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment

Lead Sponsor:

Ruijin Hospital

Collaborating Sponsors:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Huadong Hospital

Conditions:

Non-small Cell Lung Cancer

Surgery

Eligibility:

All Genders

18-75 years

Brief Summary

Lung cancer is one of the most common malignant tumors worldwide and has the highest mortality rate among malignant tumors. In recent years, with the gradual development of therapeutic modalities such...

Detailed Description

We propose to conduct a multicenter, single-arm prospective clinical study to investigate the feasibility, safety and prognosis of the conversion from pneumonectomy to lobectomy after neoadjuvant or i...

Eligibility Criteria

Inclusion

  • The patients voluntarily participate in the study, have good compliance, can cooperate with the requirements of the experiment to complete the observation and follow-up, and sign the informed consent form.
  • Aged over 18 years old, under 75 years old; male and female are not limited;
  • Pathologically confirmed non-small cell lung cancer with clinical stage T2-4N0-2, resectable non-small cell lung cancer, potentially needing pneumonectomy and receiving neoadjuvant or induction therapy.
  • ASA score: Grade I-III;
  • The cardiopulmonary function evaluation can meet the requirements for radical lung cancer surgery, and the liver and kidney functions are normal.

Exclusion

  • Those with serious cardiac, pulmonary, hepatic, and renal dysfunctions, unable to tolerate the surgery;
  • Those with uncontrollable neurological or psychiatric diseases or mental disorders, poor compliance, and being unable to cooperate and describe the treatment response.
  • Those who are going to undergo emergency surgery or palliative surgery due to lung abscess or hemoptysis.
  • Those who have been treated, or are undergoing neoadjuvant or induction radiotherapy or targeted therapy.
  • Those who have a combined history of other malignant tumors
  • Those who have a history of thoracic surgery
  • Those who are pregnant or breastfeeding women
  • Patients of childbearing age who refuse to use contraception.

Key Trial Info

Start Date :

August 31 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 31 2029

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06534489

Start Date

August 31 2023

End Date

August 31 2029

Last Update

August 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ruijin hospital

Shanghai, China, 200025